Pharmaceutical Executive, March 2020 Issue (PDF)

Article

Pharmaceutical Executive

Pharmaceutical ExecutivePharmaceutical Executive-03-01-2020
Volume 40
Issue 3

Click the title above to open the Pharmaceutical Executive March 2020 issue in an interactive PDF format.

.

External Link - Pharm Exec_March 2020.pdf

Download Issue PDF
Articles in this issue
The Multichannel Reach: Balancing the Local and Global Voice
The Multichannel Reach: Balancing the Local and Global Voice
Market Access: From Being to Becoming
Market Access: From Being to Becoming
Consider Data Before It’s a Problem
Multichannel Marketing: Integrating Omnichannel
Multichannel Marketing: Integrating Omnichannel
Wash PQ.png
Feds Target Biosimilar Anticompetitive Practices
Blood Feud Divides Europe Over Plasma Shortfalls
Multichannel PQ4.png
Social Media’s Influence in Messaging Mix
Habib Bennaceur: Following the Science
Habib Bennaceur: Following the Science
Sandy Jennings.jpg
A Bad Deal with Data?
Pharmaceutical Executive, March 2020 Issue (PDF)
Country Report: United Arab Emirates
Recent Videos
John Arena
John Arena
John Arena
James Foster
John Arena
Related Content
FDA Accepts Supplemental New Drug Application for Teva, Medincell’s Uzedy for Bipolar I Disorder

FDA Accepts Supplemental New Drug Application for Teva, Medincell’s Uzedy for Bipolar I Disorder

Don Tracy, Associate Editor
February 26th 2025
Article

The application leverages existing clinical data for Uzedy along with prior FDA findings on the safety of Udezy in patients with bipolar I disorder.

Navigating Distrust: Pharma in the Age of Social Media

Navigating Distrust: Pharma in the Age of Social Media

Miranda Schmalfuhs
February 18th 2025
Podcast

Ian Baer, Founder and CEO of Sooth, discusses how the growing distrust in social media will impact industry marketing strategies and the relationships between pharmaceutical companies and the patients they aim to serve. He also explains dark social, how to combat misinformation, closing the trust gap, and more.

FibroBiologics

Bringing Fibroblasts to the Spotlight: Q&A with FibroBiologics

PHARM EXEC
February 26th 2025
Article

These therapies may provide more stable treatments than stem cell therapies.

Revolutionizing Patient Adherence: Leveraging AI for Personalized Engagement

Revolutionizing Patient Adherence: Leveraging AI for Personalized Engagement

Miranda Schmalfuhs
February 10th 2025
Podcast

Bill Grambley, CEO of AllazoHealth, delves into the potential of AI to revolutionize patient engagement and adherence.

FDA Approves Prolacta Bioscience’s Surgifort for Infants Recovering from Gastroschisis Surgery

FDA Approves Prolacta Bioscience’s Surgifort for Infants Recovering from Gastroschisis Surgery

Don Tracy, Associate Editor
February 25th 2025
Article

Surgifort is the first FDA-approved human milk-based fortifier specifically designed for term infants recovering from gastroschisis surgery.

FDA Grants Priority Review to Merck’s Keytruda for Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma

FDA Grants Priority Review to Merck’s Keytruda for Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma

Don Tracy, Associate Editor
February 25th 2025
Article

Keytruda demonstrated a statistically significant and clinically meaningful improvement in event-free survival and major pathological response in patients with resectable locally advanced head and neck squamous cell carcinoma.